Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias

被引:40
作者
Massenkeil, G
Nagy, M
Neuburger, S
Tamm, I
Lutz, C
le Coutre, P
Rosen, O
Wernecke, KD
Dörken, B
Arnold, R
机构
[1] Univ Med Berlin, Dept Haematol & Oncol, D-13353 Berlin, Germany
[2] Univ Med Berlin, Inst Legal Med, D-13353 Berlin, Germany
[3] Univ Med Berlin, Inst Med Biometry, D-13353 Berlin, Germany
关键词
reduced-intensity conditioning; nonmyelo-ablative stem cell transplantation; standard high-dose conditioning; ALL; AML;
D O I
10.1038/sj.bmt.1705123
中图分类号
Q6 [生物物理学];
学科分类号
071011 [生物物理学];
摘要
To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high- dose conditioning. Engraftment, acute GvHD and severe infections were comparable in both groups. During the observation period, 1/25 patients (4%) after RIC and 14/50 (28%) after standard SCT died due to transplant-related causes; cumulative nonrelapse mortality (NRM) was 4% after RIC and 24% after standard SCT (P = 0.029). In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS). Overall survival (OS) was 40% after RIC and 37% after standard SCT (NS). Stage of disease, cytogenetic risk pro. le, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS. In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies.
引用
收藏
页码:683 / 689
页数:7
相关论文
共 40 条
[1]
Appelbaum FR, 1997, SEMIN ONCOL, V24, P114
[2]
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease [J].
Arnold, R ;
Massenkeil, G ;
Bornhäuser, M ;
Ehninger, G ;
Beelen, DW ;
Fauser, AA ;
Hegenbart, U ;
Hertenstein, B ;
Ho, AD ;
Knauf, W ;
Kolb, HJ ;
Kolbe, K ;
Sayer, HG ;
Schwerdtfeger, R ;
Wandt, H ;
Hoelzer, D .
LEUKEMIA, 2002, 16 (12) :2423-2428
[3]
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[4]
Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children [J].
Bader, P ;
Klingebiel, T ;
Schaudt, A ;
Theurer-Mainka, U ;
Handgretinger, R ;
Lang, P ;
Niethammer, D ;
Beck, JF .
LEUKEMIA, 1999, 13 (12) :2079-2086
[5]
AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[6]
Bornhäuser M, 2001, CLIN CANCER RES, V7, P2254
[7]
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen [J].
Chakraverty, R ;
Peggs, K ;
Chopra, R ;
Milligan, DW ;
Kottaridis, PD ;
Verfuerth, S ;
Geary, J ;
Thuraisundaram, D ;
Branson, K ;
Chakrabarti, S ;
Mahendra, P ;
Craddock, C ;
Parker, A ;
Hunter, A ;
Hale, G ;
Waldmann, H ;
Williams, CD ;
Yong, K ;
Linch, DC ;
Goldstone, AH ;
Mackinnon, S .
BLOOD, 2002, 99 (03) :1071-1078
[8]
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[9]
COX DR, 1972, J R STAT SOC B, V34, P187
[10]
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors [J].
Diaconescu, R ;
Flowers, CR ;
Storer, B ;
Sorror, ML ;
Maris, MB ;
Maloney, DG ;
Sandmaier, BM ;
Storb, R .
BLOOD, 2004, 104 (05) :1550-1558